Market cap of Nuvalent Inc. [NUVL] reaches 1.65B – now what?

Nuvalent Inc. [NASDAQ: NUVL] traded at a low on 12/23/22, posting a -2.50 loss after which it closed the day’ session at $28.44. The company report on December 13, 2022 that Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Publication provides comprehensive assessment of NVL-520’s activity spanning preclinical characterization and preliminary clinical case studies.

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Cancer Discovery, a journal of the American Association for Cancer Research, which describes the design and characterization of NVL-520 and details Nuvalent’s approach to rationally targeting ROS1. NVL-520 is currently being studied in the ongoing ARROS-1 Phase 1/2 clinical trial for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors.

The results of the trading session contributed to over 142544 shares changing hands. Over the past one week, the price volatility of Nuvalent Inc. stands at 6.30% while the volatility over the past one month is 7.34%.

The market cap for NUVL stock reached $1.65 billion, with 48.41 million shares outstanding and 46.41 million shares in the current float. Compared to the average trading volume of 377.68K shares, NUVL reached a trading volume of 142544 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Nuvalent Inc. [NUVL]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NUVL shares is $43.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NUVL stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BMO Capital Markets have made an estimate for Nuvalent Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 24, 2022.

The Average True Range (ATR) for Nuvalent Inc. is set at 2.14 The Price to Book ratio for the last quarter was 5.82, with the Price to Cash per share for the same quarter was set at 4.15.

How has NUVL stock performed recently?

Nuvalent Inc. [NUVL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.82. With this latest performance, NUVL shares dropped by -10.99% in over the last four-week period, additionally plugging by 110.51% over the last 6 months – not to mention a rise of 47.97% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NUVL stock in for the last two-week period is set at 43.08, with the RSI for the last a single of trading hit 37.01, and the three-weeks RSI is set at 47.38 for Nuvalent Inc. [NUVL]. The present Moving Average for the last 50 days of trading for this stock 29.31, while it was recorded at 28.97 for the last single week of trading, and 17.80 for the last 200 days.

Nuvalent Inc. [NUVL]: Deeper insight into the fundamentals

Return on Equity for this stock declined to -32.03, with Return on Assets sitting at -30.44.

Nuvalent Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 18.90 and a Current Ratio set at 18.90.

Insider trade positions for Nuvalent Inc. [NUVL]

There are presently around $1,287 million, or 89.20% of NUVL stock, in the hands of institutional investors. The top three institutional holders of NUVL stocks are: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with ownership of 19,341,024, which is approximately 0% of the company’s market cap and around 5.10% of the total institutional ownership; FMR LLC, holding 6,446,671 shares of the stock with an approximate value of $183.34 million in NUVL stocks shares; and BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, currently with $97.49 million in NUVL stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Nuvalent Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 34 institutional holders increased their position in Nuvalent Inc. [NASDAQ:NUVL] by around 1,657,963 shares. Additionally, 22 investors decreased positions by around 2,308,512 shares, while 13 investors held positions by with 41,301,423 shares. The mentioned changes placed institutional holdings at 45,267,898 shares, according to the latest SEC report filing. NUVL stock had 12 new institutional investments in for a total of 534,781 shares, while 6 institutional investors sold positions of 1,198,781 shares during the same period.


Please enter your comment!
Please enter your name here